The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma

by Jaya Unnithan, Brian I. Rini
Published 2007-01-01

Treatment of Refractory Metastatic Renal Cell Carcinoma

by Joseph A. Vento, Brian I. Rini
Published 2022-10-01

Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma

by Matthew D. Tucker, Brian I. Rini
Published 2020-09-01

Novel agents in renal carcinoma: a reality check

by Yana G. Najjar, Brian I. Rini
Published 2012-07-01

Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma

by James Brugarolas, Michael B Atkins, Brian I Rini
Published 2023-03-01

Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?

by Bo Zhao, Laura S. Wood, Karen James, Brian I. Rini
Published 2015-01-01

Emerging Targets in Clear Cell Renal Cell Carcinoma

by Yu-Wei Chen, Brian I. Rini, Kathryn E. Beckermann
Published 2022-10-01

Specific immunotherapy in renal cancer: a systematic review

by Armin Hirbod-Mobarakeh, Hesam Addin Gordan, Zahra Zahiri, Mohammad Mirshahvalad, Sima Hosseinverdi, Brian I. Rini, Nima Rezaei
Published 2017-02-01

Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports

by Matthew D. Tucker, Kathryn E. Beckermann, Jennifer B. Gordetsky, Giovanna A. Giannico, Nancy B. Davis, Brian I. Rini
Published 2020-12-01

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab

by Tian Zhang, Brian I. Rini, Moshe C. Ornstein, Daniel J. George, Chester Kao, Landon C. Brown, Kunal Desai, Emily N. Kinsey
Published 2021-09-01

Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

by Yoshihiko Tomita, Hirotsugu Uemura, Mototsugu Oya, Nobuo Shinohara, Tomonori Habuchi, Yosuke Fujii, Yoichi Kamei, Yoshiko Umeyama, Angel H. Bair, Brian I. Rini
Published 2019-01-01

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

by Moshe C. Ornstein, Laura S. Wood, Brian P. Hobbs, Kimberly D. Allman, Allison Martin, Michael Bevan, Timothy D. Gilligan, Jorge A. Garcia, Brian I. Rini
Published 2019-05-01

HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism

by Weinan Du, Luchang Zhang, Adina Brett-Morris, Brittany Aguila, Janos Kerner, Charles L. Hoppel, Michelle Puchowicz, Dolors Serra, Laura Herrero, Brian I. Rini, Steven Campbell, Scott M. Welford
Published 2017-11-01

Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab

by Haris Zahoor, Pedro C. Barata, Xuefei Jia, Allison Martin, Kimberly D. Allman, Laura S. Wood, Timothy D. Gilligan, Petros Grivas, Moshe C. Ornstein, Jorge A. Garcia, Brian I. Rini
Published 2018-10-01

MBOAT7-driven phosphatidylinositol remodeling promotes the progression of clear cell renal carcinoma

by Chase K.A. Neumann, Daniel J. Silver, Varadharajan Venkateshwari, Renliang Zhang, C. Alicia Traughber, Christopher Przybycin, Defne Bayik, Jonathan D. Smith, Justin D. Lathia, Brian I. Rini, J. Mark Brown
Published 2020-04-01

Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations

by Yasser Ged, Ruby Gupta, Cihan Duzgol, Andrea Knezevic, Natalie Shapnik, Ritesh Kotecha, Martin H. Voss, Darren R. Feldman, Oguz Akin, Sujata Patil, Robert J. Motzer, Brian I. Rini, Chung-Han Lee
Published 2020-07-01

Differing von Hippel Lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma

by Susan A.J. Vaziri, Emmanuel J Tavares, Ali R Golshayan, Brian I Rini, Hakan eAydin, Ming eZhou, Linda eSercia, Laura eWood, Mahrukh K Ganapathi, Ronald M Bukowski, Ram eGanapathi
Published 2012-05-01

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

by Chung-Wei Lee, Thomas Powles, Sabina Signoretti, David F McDermott, Sumanta K Pal, Toni K Choueiri, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Scott S Tykodi, Nizar M Tannir, Saurabh Gupta, Ruiyun Jiang
Published 2022-12-01

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

by Vadim S. Koshkin, Pedro C. Barata, Tian Zhang, Daniel J. George, Michael B. Atkins, William J. Kelly, Nicholas J. Vogelzang, Sumanta K. Pal, JoAnn Hsu, Leonard J. Appleman, Moshe C. Ornstein, Timothy Gilligan, Petros Grivas, Jorge A. Garcia, Brian I. Rini
Published 2018-01-01

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

by Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, Lionel D Lewis, Todd M Bauer, David F McDermott, Michael Carducci, Christian Kollmannsberger, Brian I Rini, Daniel Y C Heng, Jennifer Knox, Martin H Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J Hammers
Published 2018-10-01